1. Pink Sheet
  2. >>Geography
  3. >>Europe

EU Rips Up Competition Rulebook To Allow Collaboration On Coronavirus

Medicines For Europe Welcomes European Commission’s Temporary Framework

 
• By Dave Wallace

A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.

Europe_Map_Nodes
THE COMMISSION’S TEMPORARY FRAMEWORK WILL ALLOW A JOINED-UP APPROACH • Source: Shutterstock

A temporary framework has been adopted by the European Commission that will allow companies and industry associations to co-ordinate their activities as part of efforts to tackle supply obstacles in the face of the coronavirus pandemic. The framework allows industry to co-operate without raising competition concerns and has been welcomed by European off-patent association Medicines for Europe.

Setting out the temporary framework, the commission acknowledged that “measures to adapt production, stock management and, potentially, distribution in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Why Chiesi’s Raxone Faced a Decade-Long Wait For English Funding

 
• By Eliza Slawther

Chiesi’s orphan drug Raxone has secured an English funding recommendation for the treatment of Leber's hereditary optic neuropathy, a decade after the orphan drug was approved for marketing. Chiesi told the Pink Sheet about its “long, and often challenging” road to reimbursement.

Europe Eyes First Therapies For PSC And cALD In Latest EMA Drug Filings

 
• By Neena Brizmohun

Norucholic acid and leriglitazone, for treating primary sclerosing cholangitis and cerebral adrenoleukodystrophy, respectively, are among 12 new drugs that the European Medicines Agency has started to review for potential EU marketing approval.

New Advisory Group To Shape UK’s Simplified Informed Consent Process

 
• By Anabel Costa-Ferreira

Although the UK Health Research Authority’s initial proposal for simplified informed consent was rejected by stakeholders, it has yielded valuable insights into reducing trial burden and widening access

EU Must Up Competitiveness To Counter US Tariffs And Pricing Woes For SMEs

 
• By Francesca Bruce

Companies in Europe cannot delay business decision making much longer to wait for more certainty on major US policy shifts on tariffs and pricing.

More from Geography